Reuters Reiterates Outperform Rating on Manas Petroleum

Reuters Reiterates Outperform Rating on Manas Petroleum

To view the full report go to http://www.undiscoveredequities.com/mnap_reuters_march_2010.pdf

Financial giant predicts Manas shares likely to outperform the market.

If you are as bullish on oil stocks in general and specifically bullish on Manas Petroleum shares as I am, Reuters coverage of Manas Petroleum, will be good news. In it, Thomson Reuters, one of the world’s largest stock market analytics firms which is also ranked as one of Britain’s most respected companies, has singled out Manas Petroleum (MNAP) shares as likely to outperform the market based on its “proprietary quantitative model”. Reuter’s description of what this "technical" ranking means is quoted below.

“We cannot guarantee that each stock will perform in accordance with its rank. But we do believe that over the long term, stocks rated Outperform (30% of all stocks we rate) will, in the aggregate, outperform stocks rated Neutral (40% of all stocks we rate), and that stocks rated Neutral will, in the aggregate, outperform stocks rated Underperform (30%). All analysis is based on publicly available company financials, fundamental ratios, relative rankings of financial data and ratios, and observed equity prices”

About Manas Petroleum:

Manas Petroleum is an international oil and gas company, focusing on activities in South-Eastern Europe, Central Asia and South America. Details of these projects are located on the Company's website: www.manaspete.com

Undiscovered Equities is currently offering a trial subscription. For more information please call 1-800-404-8982 or visit our website at www.undiscoveredequities.com

Nutra Pharma to Exhibit at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C. (OTCBB:NPHC)

March 11, 2010
Nutra Pharma will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12th IDGA Battlefield Healthcare Summit from March 29th through March 31st in Washington, D.C.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C. The IDGA Battlefield Healthcare Summit is considered one of the premier military healthcare conferences and the start to the IDGA’s Military Health Week.

“The IDGA Battlefield Healthcare Summit is one of the most highly regarded forums for discussing best practices and next generation combat medicine and rehabilitative care,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We believe this summit provides an excellent venue for introducing our Nyloxin branded pain relievers to the military healthcare community,” he concluded.

Nutra Pharma first introduced Nyloxin OTC in November 2009 as a treatment for moderate to severe (Stage 2) chronic pain. Nyloxin OTC will be available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additionally, the Company introduced Nyloxin Rx in October 2009 as a prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function.
Both Nyloxin OTC and Nyloxin Rx are manufactured by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, and do not rely on the use of opioids or acetaminophen for their pain relieving action. Undiscovered Equities is currently offering a trial subscription. For more information please call 1-800-404-8982 or visit our website at www.undiscoveredequities.com

Sincerely,

Kevin McKnight
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
1-800-404-8982
www.undiscoveredequities.com

Houston American Energy Once Again Highlighted In The Wall Street Journal

Houston American Energy's Stake in Colombia May Pay Off

Thursday, March 11, 2010

The Wall Street Journal
by Jennifer Cummings

Houston American Energy Corp., a small energy company focused on Colombia, may soon reap big rewards from its well-established presence in that country.

Houston American and partner South Korean energy giant SK Energy Co. are expected to begin drilling at a nearly 550-square-mile oil exploration block in Colombia called CPO 4 by the end of the year.

The block is nestled between projects that have been producing solid results for other companies, and if Houston American has similar success to its neighbors, its stock, which was trading at around $13 Tuesday, could easily reach $50 over the next two years, Global Hunter Securities analyst Philip McPherson said.

Colombia has become a magnet for exploration and production companies in recent years as the country has become more business friendly under President Alvaro Uribe Velez.

At a time when energy companies are increasingly relying on unconventional methods to tap into new sources of oil, in Colombia there is still a lot of oil that can be accessed with more cost-effective, conventional techniques.

"Imagine going back to Texas in the 20s," Houston American Chief Financial Officer James Jacobs said.

Houston American's stock began going on a tear in mid-February when Colombia-based Petrominerales Ltd.. announced huge production rates in acreage that abuts the CPO 4.

Houston American shares have surged since Petrominerales announced Feb. 15 that its latest well produced at a rate of 15,800 barrels of oil per day. That came after an initial well there flowed at 12,400 barrels per day. Currently, Houston American produces about 1,000 to 1,200 barrels of oil a day via its other projects in Colombia, Mr. Jacobs said. A chunk of revenue derived from the CPO 4 block will go to partner SK Energy and the Colombian government, but if just one well there produces at rates similar to Petrominerales' wells, Houston American's revenue will at least double, Mr. McPherson said.

To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.

Sincerely,

Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com

Nutra Pharma's Over-the-Counter (OTC) Pain Reliever, Cobroxin, to be Sold in Walgreens (OTCBB:NPHC)

Cobroxin, an Over-the-Counter (OTC) Pain Reliever Indicated for Treating Moderate to Severe (Stage 2) Chronic Pain, Will Be Available for Purchase in Walgreens by May 1, 2010

DELRAY BEACH, Fla., Mar 10, 2010 -- XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be available for purchase in Walgreens by May 1, 2010. Walgreens is considered one of the nation's largest pharmacy chains with 7,162 drugstores located throughout the United States.

"As one of the largest and most well recognized pharmacy chains in North America, we are pleased that Walgreens has chosen to offer Cobroxin for sale in its drugstores throughout the United States," commented Frank Rizzo, President and CEO of XenaCare Holdings. "We look forward to working closely with Walgreens as we prepare for this launch and finalize our promotional strategy to support ongoing sales efforts by the retailer," he added.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.

Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- Long Lasting

XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB:NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.

About Nutra Pharma Corp.
Nutra Pharma Corporation (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.

www.undiscoveredequities.net

www.nutrapharma.com

www.Cobroxin.com
Undiscovered Equities is currently offering a complimentary trial subscription.

To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.

Sincerely,
Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com

Cobroxin for Chronic Pain TV Commercial now on YouTube

Cobroxin for Chronic Pain TV Commercial now on YouTube

To view the video click here

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information visit http://www.cobroxin.com/ or http://www.nutrapharma.com./

Undiscovered Equities is currently offering a complimentary trial subscription.

To view our newsletter on a complimentary trial basis and take advantage of our other services go to http://www.undiscoveredequities.com/ and join our email list on our home page.

Sincerely,

Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
http://app.streamsend.com/c/9242661/1445/zUQv2zM/nS0Q?redirect_to=http%3A%2F%2Fwww.undiscoveredequities.com

Cobroxin for Chronic Pain TV Commercial now on YouTube

Cobroxin for Chronic Pain TV Commercial now on YouTube

To view the video click here

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information visit http://www.cobroxin.com/ or http://www.nutrapharma.com./

Undiscovered Equities is currently offering a complimentary trial subscription.

To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.

Sincerely,

Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com

Cobroxin Testimonials from the 2010 World MoneyShow in Orlando, Florida Now on YouTube

Cobroxin Testimonials from the 2010 World MoneyShow in Orlando, Florida now on YouTube.

To view the video click here

Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis. For more information visit http://www.Cobroxin.com or http://www.NutraPharma.com.

Undiscovered Equities is currently offering a complimentary trial subscription.

To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.

Sincerely,

Kevin McKnight
1-800-404-8982
Undiscovered Equities, Inc.
101 Plaza Real, Suite 212
Boca Raton, FL 33432
www.undiscoveredequities.com